Vivus announced a near doubling of Qsymia prescriptions in December compared to November. Of course, if Vivus know the total number of Qsymia prescriptions for the fourth quarter, the company also knows how much revenue was generated from those Qsymia prescriptiosn. My guess is Vivus chose to publicize prescriptions totals while keeping sales hidden because the latter number is small and disappointing.
Likewise, Spectrum could have easily given us fourth-quarter revenue, including all-important Fusilev sales, like the company has done in the past when it had something to brag about. Monthly Fusilev third-party sales estimates have been in decline for the fourth quarter, however, which likely explains Spectrum's silence.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV